nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—RET—autonomic nervous system—Gilles de la Tourette syndrome	0.0407	0.0428	CbGeAlD
Ruxolitinib—ANKK1—nervous system—Gilles de la Tourette syndrome	0.017	0.0179	CbGeAlD
Ruxolitinib—PRKG2—nervous system—Gilles de la Tourette syndrome	0.0141	0.0148	CbGeAlD
Ruxolitinib—PRKG2—central nervous system—Gilles de la Tourette syndrome	0.0136	0.0143	CbGeAlD
Ruxolitinib—GRK1—nervous system—Gilles de la Tourette syndrome	0.0134	0.0141	CbGeAlD
Ruxolitinib—PRKCE—nervous system—Gilles de la Tourette syndrome	0.0131	0.0138	CbGeAlD
Ruxolitinib—GRK1—central nervous system—Gilles de la Tourette syndrome	0.0129	0.0136	CbGeAlD
Ruxolitinib—PRKCE—central nervous system—Gilles de la Tourette syndrome	0.0127	0.0133	CbGeAlD
Ruxolitinib—RPS6KA6—nervous system—Gilles de la Tourette syndrome	0.0126	0.0133	CbGeAlD
Ruxolitinib—PLK1—nervous system—Gilles de la Tourette syndrome	0.0126	0.0133	CbGeAlD
Ruxolitinib—MAST1—nervous system—Gilles de la Tourette syndrome	0.0126	0.0133	CbGeAlD
Ruxolitinib—PLK1—central nervous system—Gilles de la Tourette syndrome	0.0122	0.0128	CbGeAlD
Ruxolitinib—RPS6KA6—central nervous system—Gilles de la Tourette syndrome	0.0122	0.0128	CbGeAlD
Ruxolitinib—MAST1—central nervous system—Gilles de la Tourette syndrome	0.0122	0.0128	CbGeAlD
Ruxolitinib—DCLK3—nervous system—Gilles de la Tourette syndrome	0.012	0.0126	CbGeAlD
Ruxolitinib—DCLK3—central nervous system—Gilles de la Tourette syndrome	0.0115	0.0121	CbGeAlD
Ruxolitinib—PRKG2—brain—Gilles de la Tourette syndrome	0.0108	0.0113	CbGeAlD
Ruxolitinib—PLK3—nervous system—Gilles de la Tourette syndrome	0.0105	0.0111	CbGeAlD
Ruxolitinib—GRK1—brain—Gilles de la Tourette syndrome	0.0103	0.0108	CbGeAlD
Ruxolitinib—PLK3—central nervous system—Gilles de la Tourette syndrome	0.0101	0.0107	CbGeAlD
Ruxolitinib—PRKCE—brain—Gilles de la Tourette syndrome	0.01	0.0106	CbGeAlD
Ruxolitinib—CAMK1—nervous system—Gilles de la Tourette syndrome	0.00986	0.0104	CbGeAlD
Ruxolitinib—JAK1—midbrain—Gilles de la Tourette syndrome	0.00984	0.0103	CbGeAlD
Ruxolitinib—DCLK1—midbrain—Gilles de la Tourette syndrome	0.00984	0.0103	CbGeAlD
Ruxolitinib—PLK1—brain—Gilles de la Tourette syndrome	0.00966	0.0101	CbGeAlD
Ruxolitinib—RPS6KA6—brain—Gilles de la Tourette syndrome	0.00966	0.0101	CbGeAlD
Ruxolitinib—MAST1—brain—Gilles de la Tourette syndrome	0.00966	0.0101	CbGeAlD
Ruxolitinib—MARK2—nervous system—Gilles de la Tourette syndrome	0.00957	0.0101	CbGeAlD
Ruxolitinib—CAMK1—central nervous system—Gilles de la Tourette syndrome	0.00949	0.00998	CbGeAlD
Ruxolitinib—DAPK2—midbrain—Gilles de la Tourette syndrome	0.00939	0.00987	CbGeAlD
Ruxolitinib—MARK2—central nervous system—Gilles de la Tourette syndrome	0.00922	0.00969	CbGeAlD
Ruxolitinib—DCLK3—brain—Gilles de la Tourette syndrome	0.00915	0.00962	CbGeAlD
Ruxolitinib—DAPK3—midbrain—Gilles de la Tourette syndrome	0.00883	0.00928	CbGeAlD
Ruxolitinib—BMPR2—midbrain—Gilles de la Tourette syndrome	0.00823	0.00865	CbGeAlD
Ruxolitinib—JAK3—nervous system—Gilles de la Tourette syndrome	0.00814	0.00856	CbGeAlD
Ruxolitinib—JAK1—nervous system—Gilles de la Tourette syndrome	0.00809	0.0085	CbGeAlD
Ruxolitinib—DCLK1—nervous system—Gilles de la Tourette syndrome	0.00809	0.0085	CbGeAlD
Ruxolitinib—PLK3—brain—Gilles de la Tourette syndrome	0.00806	0.00847	CbGeAlD
Ruxolitinib—CAMK1D—nervous system—Gilles de la Tourette syndrome	0.00789	0.0083	CbGeAlD
Ruxolitinib—PHKG2—nervous system—Gilles de la Tourette syndrome	0.00785	0.00825	CbGeAlD
Ruxolitinib—JAK3—central nervous system—Gilles de la Tourette syndrome	0.00784	0.00824	CbGeAlD
Ruxolitinib—JAK1—central nervous system—Gilles de la Tourette syndrome	0.00779	0.00819	CbGeAlD
Ruxolitinib—DCLK1—central nervous system—Gilles de la Tourette syndrome	0.00779	0.00819	CbGeAlD
Ruxolitinib—LTK—brain—Gilles de la Tourette syndrome	0.00778	0.00818	CbGeAlD
Ruxolitinib—CAMK1D—central nervous system—Gilles de la Tourette syndrome	0.0076	0.00799	CbGeAlD
Ruxolitinib—STK16—nervous system—Gilles de la Tourette syndrome	0.00759	0.00798	CbGeAlD
Ruxolitinib—PHKG2—central nervous system—Gilles de la Tourette syndrome	0.00756	0.00794	CbGeAlD
Ruxolitinib—HIPK2—nervous system—Gilles de la Tourette syndrome	0.00755	0.00794	CbGeAlD
Ruxolitinib—CAMK1—brain—Gilles de la Tourette syndrome	0.00754	0.00792	CbGeAlD
Ruxolitinib—MAP3K19—nervous system—Gilles de la Tourette syndrome	0.0074	0.00778	CbGeAlD
Ruxolitinib—CAMK2G—midbrain—Gilles de la Tourette syndrome	0.00737	0.00774	CbGeAlD
Ruxolitinib—BMP2K—midbrain—Gilles de la Tourette syndrome	0.00737	0.00774	CbGeAlD
Ruxolitinib—MARK2—brain—Gilles de la Tourette syndrome	0.00732	0.00769	CbGeAlD
Ruxolitinib—STK16—central nervous system—Gilles de la Tourette syndrome	0.00731	0.00768	CbGeAlD
Ruxolitinib—LRRK2—midbrain—Gilles de la Tourette syndrome	0.0073	0.00767	CbGeAlD
Ruxolitinib—HIPK2—central nervous system—Gilles de la Tourette syndrome	0.00727	0.00764	CbGeAlD
Ruxolitinib—DAPK3—nervous system—Gilles de la Tourette syndrome	0.00725	0.00763	CbGeAlD
Ruxolitinib—CLK2—nervous system—Gilles de la Tourette syndrome	0.00719	0.00755	CbGeAlD
Ruxolitinib—MAP3K19—central nervous system—Gilles de la Tourette syndrome	0.00712	0.00749	CbGeAlD
Ruxolitinib—DAPK3—central nervous system—Gilles de la Tourette syndrome	0.00698	0.00734	CbGeAlD
Ruxolitinib—ROCK1—nervous system—Gilles de la Tourette syndrome	0.00697	0.00732	CbGeAlD
Ruxolitinib—CLK2—central nervous system—Gilles de la Tourette syndrome	0.00692	0.00727	CbGeAlD
Ruxolitinib—DYRK1A—nervous system—Gilles de la Tourette syndrome	0.00679	0.00714	CbGeAlD
Ruxolitinib—TAOK2—brain—Gilles de la Tourette syndrome	0.00677	0.00712	CbGeAlD
Ruxolitinib—BMPR2—nervous system—Gilles de la Tourette syndrome	0.00677	0.00711	CbGeAlD
Ruxolitinib—ROCK1—central nervous system—Gilles de la Tourette syndrome	0.00671	0.00705	CbGeAlD
Ruxolitinib—MAP3K7—midbrain—Gilles de la Tourette syndrome	0.00663	0.00696	CbGeAlD
Ruxolitinib—DYRK1A—central nervous system—Gilles de la Tourette syndrome	0.00654	0.00688	CbGeAlD
Ruxolitinib—BMPR2—central nervous system—Gilles de la Tourette syndrome	0.00651	0.00685	CbGeAlD
Ruxolitinib—TYK2—midbrain—Gilles de la Tourette syndrome	0.00651	0.00684	CbGeAlD
Ruxolitinib—IRAK1—midbrain—Gilles de la Tourette syndrome	0.00642	0.00675	CbGeAlD
Ruxolitinib—MKNK2—midbrain—Gilles de la Tourette syndrome	0.00642	0.00675	CbGeAlD
Ruxolitinib—RET—midbrain—Gilles de la Tourette syndrome	0.00626	0.00658	CbGeAlD
Ruxolitinib—JAK3—brain—Gilles de la Tourette syndrome	0.00622	0.00654	CbGeAlD
Ruxolitinib—JAK1—brain—Gilles de la Tourette syndrome	0.00618	0.0065	CbGeAlD
Ruxolitinib—DCLK1—brain—Gilles de la Tourette syndrome	0.00618	0.0065	CbGeAlD
Ruxolitinib—PLK4—brain—Gilles de la Tourette syndrome	0.00614	0.00646	CbGeAlD
Ruxolitinib—CAMK2G—nervous system—Gilles de la Tourette syndrome	0.00606	0.00637	CbGeAlD
Ruxolitinib—BMP2K—nervous system—Gilles de la Tourette syndrome	0.00606	0.00637	CbGeAlD
Ruxolitinib—CAMK1D—brain—Gilles de la Tourette syndrome	0.00603	0.00634	CbGeAlD
Ruxolitinib—LRRK2—nervous system—Gilles de la Tourette syndrome	0.006	0.00631	CbGeAlD
Ruxolitinib—PHKG2—brain—Gilles de la Tourette syndrome	0.006	0.00631	CbGeAlD
Ruxolitinib—DAPK2—brain—Gilles de la Tourette syndrome	0.0059	0.0062	CbGeAlD
Ruxolitinib—CAMK2G—central nervous system—Gilles de la Tourette syndrome	0.00583	0.00613	CbGeAlD
Ruxolitinib—BMP2K—central nervous system—Gilles de la Tourette syndrome	0.00583	0.00613	CbGeAlD
Ruxolitinib—STK16—brain—Gilles de la Tourette syndrome	0.0058	0.0061	CbGeAlD
Ruxolitinib—LRRK2—central nervous system—Gilles de la Tourette syndrome	0.00578	0.00607	CbGeAlD
Ruxolitinib—HIPK2—brain—Gilles de la Tourette syndrome	0.00577	0.00607	CbGeAlD
Ruxolitinib—MAP3K3—midbrain—Gilles de la Tourette syndrome	0.0057	0.006	CbGeAlD
Ruxolitinib—MAP3K19—brain—Gilles de la Tourette syndrome	0.00565	0.00594	CbGeAlD
Ruxolitinib—DAPK3—brain—Gilles de la Tourette syndrome	0.00555	0.00583	CbGeAlD
Ruxolitinib—MAP3K2—nervous system—Gilles de la Tourette syndrome	0.0055	0.00578	CbGeAlD
Ruxolitinib—CLK2—brain—Gilles de la Tourette syndrome	0.00549	0.00577	CbGeAlD
Ruxolitinib—TYK2—nervous system—Gilles de la Tourette syndrome	0.00535	0.00562	CbGeAlD
Ruxolitinib—ROCK1—brain—Gilles de la Tourette syndrome	0.00532	0.0056	CbGeAlD
Ruxolitinib—MAP3K2—central nervous system—Gilles de la Tourette syndrome	0.00529	0.00556	CbGeAlD
Ruxolitinib—MKNK2—nervous system—Gilles de la Tourette syndrome	0.00528	0.00555	CbGeAlD
Ruxolitinib—TAOK3—midbrain—Gilles de la Tourette syndrome	0.0052	0.00547	CbGeAlD
Ruxolitinib—DYRK1A—brain—Gilles de la Tourette syndrome	0.00519	0.00546	CbGeAlD
Ruxolitinib—BMPR2—brain—Gilles de la Tourette syndrome	0.00517	0.00544	CbGeAlD
Ruxolitinib—TYK2—central nervous system—Gilles de la Tourette syndrome	0.00515	0.00541	CbGeAlD
Ruxolitinib—RET—nervous system—Gilles de la Tourette syndrome	0.00515	0.00541	CbGeAlD
Ruxolitinib—MKNK2—central nervous system—Gilles de la Tourette syndrome	0.00508	0.00534	CbGeAlD
Ruxolitinib—RET—central nervous system—Gilles de la Tourette syndrome	0.00496	0.00521	CbGeAlD
Ruxolitinib—NUAK2—brain—Gilles de la Tourette syndrome	0.00494	0.0052	CbGeAlD
Ruxolitinib—JAK2—nervous system—Gilles de la Tourette syndrome	0.00487	0.00512	CbGeAlD
Ruxolitinib—MAP3K3—nervous system—Gilles de la Tourette syndrome	0.00469	0.00493	CbGeAlD
Ruxolitinib—JAK2—central nervous system—Gilles de la Tourette syndrome	0.00468	0.00492	CbGeAlD
Ruxolitinib—CAMK2G—brain—Gilles de la Tourette syndrome	0.00463	0.00487	CbGeAlD
Ruxolitinib—BMP2K—brain—Gilles de la Tourette syndrome	0.00463	0.00487	CbGeAlD
Ruxolitinib—LRRK2—brain—Gilles de la Tourette syndrome	0.00459	0.00482	CbGeAlD
Ruxolitinib—MAP3K3—central nervous system—Gilles de la Tourette syndrome	0.00452	0.00475	CbGeAlD
Ruxolitinib—TAOK3—nervous system—Gilles de la Tourette syndrome	0.00428	0.00449	CbGeAlD
Ruxolitinib—MAP3K2—brain—Gilles de la Tourette syndrome	0.0042	0.00442	CbGeAlD
Ruxolitinib—MAP3K7—brain—Gilles de la Tourette syndrome	0.00416	0.00438	CbGeAlD
Ruxolitinib—LRRK2—Parkinsons Disease Pathway—SLC6A3—Gilles de la Tourette syndrome	0.00413	0.0849	CbGpPWpGaD
Ruxolitinib—TAOK3—central nervous system—Gilles de la Tourette syndrome	0.00412	0.00433	CbGeAlD
Ruxolitinib—TYK2—brain—Gilles de la Tourette syndrome	0.00409	0.0043	CbGeAlD
Ruxolitinib—IRAK1—brain—Gilles de la Tourette syndrome	0.00403	0.00424	CbGeAlD
Ruxolitinib—MKNK2—brain—Gilles de la Tourette syndrome	0.00403	0.00424	CbGeAlD
Ruxolitinib—RET—brain—Gilles de la Tourette syndrome	0.00394	0.00414	CbGeAlD
Ruxolitinib—JAK2—Serotonin Receptor 2 and STAT3 Signaling—HTR2A—Gilles de la Tourette syndrome	0.00386	0.0793	CbGpPWpGaD
Ruxolitinib—JAK2—brain—Gilles de la Tourette syndrome	0.00372	0.00391	CbGeAlD
Ruxolitinib—MAP3K3—brain—Gilles de la Tourette syndrome	0.00358	0.00377	CbGeAlD
Ruxolitinib—RET—Dopaminergic Neurogenesis—SLC6A3—Gilles de la Tourette syndrome	0.00346	0.0711	CbGpPWpGaD
Ruxolitinib—TAOK3—brain—Gilles de la Tourette syndrome	0.00327	0.00344	CbGeAlD
Ruxolitinib—PRKCE—Hypothetical Network for Drug Addiction—DRD4—Gilles de la Tourette syndrome	0.00276	0.0567	CbGpPWpGaD
Ruxolitinib—PRKCE—Hypothetical Network for Drug Addiction—DRD2—Gilles de la Tourette syndrome	0.00257	0.0528	CbGpPWpGaD
Ruxolitinib—RET—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.00146	0.0299	CbGpPWpGaD
Ruxolitinib—ROCK1—Sema4D in semaphorin signaling—MET—Gilles de la Tourette syndrome	0.00131	0.027	CbGpPWpGaD
Ruxolitinib—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.0013	0.00137	CbGeAlD
Ruxolitinib—PLK3—Direct p53 effectors—MET—Gilles de la Tourette syndrome	0.00127	0.026	CbGpPWpGaD
Ruxolitinib—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00125	0.00131	CbGeAlD
Ruxolitinib—PRKG2—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00118	0.0243	CbGpPWpGaD
Ruxolitinib—PRKG2—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00115	0.0236	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.00113	0.0233	CbGpPWpGaD
Ruxolitinib—PRKG2—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00107	0.022	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00106	0.0218	CbGpPWpGaD
Ruxolitinib—DYRK1A—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00101	0.0207	CbGpPWpGaD
Ruxolitinib—DYRK1A—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000978	0.0201	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.000975	0.02	CbGpPWpGaD
Ruxolitinib—ROCK1—Stabilization and expansion of the E-cadherin adherens junction—MET—Gilles de la Tourette syndrome	0.000923	0.0189	CbGpPWpGaD
Ruxolitinib—DYRK1A—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000911	0.0187	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000812	0.0167	CbGpPWpGaD
Ruxolitinib—RET—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000637	0.0131	CbGpPWpGaD
Ruxolitinib—ROCK1—Semaphorin interactions—MET—Gilles de la Tourette syndrome	0.000635	0.013	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000607	0.0125	CbGpPWpGaD
Ruxolitinib—CAMK2G—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000554	0.0114	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000516	0.0106	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Axon guidance—MET—Gilles de la Tourette syndrome	0.000442	0.00908	CbGpPWpGaD
Ruxolitinib—PRKCE—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000439	0.00901	CbGpPWpGaD
Ruxolitinib—CAMK2G—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000424	0.00871	CbGpPWpGaD
Ruxolitinib—PRKCE—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000393	0.00806	CbGpPWpGaD
Ruxolitinib—ROCK1—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000369	0.00758	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000316	0.00648	CbGpPWpGaD
Ruxolitinib—JAK1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000285	0.00585	CbGpPWpGaD
Ruxolitinib—ROCK1—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000276	0.00566	CbGpPWpGaD
Ruxolitinib—MAP3K7—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000269	0.00552	CbGpPWpGaD
Ruxolitinib—TYK2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00021	0.00432	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000197	0.00406	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000192	0.00394	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000192	0.00394	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000186	0.00383	CbGpPWpGaD
Ruxolitinib—JAK1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000183	0.00376	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00018	0.00371	CbGpPWpGaD
Ruxolitinib—ROCK1—Axon guidance—MET—Gilles de la Tourette syndrome	0.00018	0.0037	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000179	0.00368	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000179	0.00367	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000175	0.0036	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000174	0.00358	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000174	0.00356	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000167	0.00342	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000163	0.00335	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000163	0.00335	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000162	0.00333	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000162	0.00332	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000159	0.00327	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000158	0.00325	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000151	0.00311	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000151	0.0031	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000148	0.00303	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000147	0.00302	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000143	0.00294	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000141	0.0029	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000139	0.00286	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000137	0.00281	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000137	0.00281	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000135	0.00277	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000131	0.00268	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00013	0.00267	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00013	0.00266	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000128	0.00264	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000128	0.00263	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000128	0.00262	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000126	0.0026	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000125	0.00257	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000124	0.00255	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000122	0.0025	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000118	0.00242	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000116	0.00238	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000114	0.00235	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000114	0.00233	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000106	0.00218	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000106	0.00217	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000103	0.00212	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000103	0.00211	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000102	0.0021	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—MET—Gilles de la Tourette syndrome	9.64e-05	0.00198	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	9.61e-05	0.00197	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	9.59e-05	0.00197	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	9.58e-05	0.00197	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	9.33e-05	0.00192	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	9.08e-05	0.00187	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	8.94e-05	0.00184	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	8.93e-05	0.00183	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	8.69e-05	0.00179	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	8.68e-05	0.00178	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	8.25e-05	0.00169	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	8.11e-05	0.00167	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8.09e-05	0.00166	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	8.02e-05	0.00165	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	7.79e-05	0.0016	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.69e-05	0.00158	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.57e-05	0.00155	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.47e-05	0.00153	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.34e-05	0.00151	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MET—Gilles de la Tourette syndrome	7.31e-05	0.0015	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.29e-05	0.0015	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.26e-05	0.00149	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.07e-05	0.00145	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.96e-05	0.00143	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.84e-05	0.00141	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.71e-05	0.00138	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.59e-05	0.00135	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	6.09e-05	0.00125	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.85e-05	0.0012	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.68e-05	0.00117	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.68e-05	0.00117	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.66e-05	0.00116	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.51e-05	0.00113	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.51e-05	0.00113	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.35e-05	0.0011	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.29e-05	0.00109	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.14e-05	0.00105	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.08e-05	0.00104	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.98e-05	0.00102	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.87e-05	0.001	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.79e-05	0.000984	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.61e-05	0.000948	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.3e-05	0.000884	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.18e-05	0.000858	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.89e-05	0.000799	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	3.85e-05	0.00079	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.7e-05	0.000761	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.6e-05	0.000739	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.49e-05	0.000716	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.73e-05	0.00056	CbGpPWpGaD
